Reference 2019-570

REF:          2019-570 

Subject:      Hereditary angioedema 

 

Request:

  1. Does your trust treat Hereditary angioedema HAE? [Yes/No]
  2. In the last 6 months, how many patients with Hereditary angioedema (HAE) have been treated with,
  • Berint
  • Cinryze
  • Firazyr
  • Ruconest
  • Takhzyro
  • Tranexamic acid
  • Other

 

  1. Does your trust treat Immune thrombocytopenia purpura ITP? [Yes/No]
  2. Over the past 6 months, how many patients with persistent / chronic* Immune thrombocytopenia purpura [ITP] have you treated [include all treatments such as steroids, splenectomy, immune globulins, Rituximab and TPOs]?
  3. Over the past 6 months, how many patients with persistent / chronic* Immune thrombocytopenia purpura [ITP] were new to treatment with the following;
  • Eltrombopag [Revolade]
  • Romiplostim [Nplate]
  1. At what line of treatment would you currently use a TPO in an ITP patient: 4th line, 3rd line, 2nd line or 1st line.
  2. Over the past 6 months, how many patients have you treated with the following conditions and treatments. If None, please state None.

 

  Total patients Eltrombopag [Revolade] Romiplostim [Nplate]
Immune thrombocytopenia purpura [ITP]      
Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy      
Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation      
Chemotherapy induced thrombocytopenia (CIT)      
Myelodysplastic syndromes (MDS)      

 

Response:

Please find information attached.

2019-570 – FOI Request – Hereditary angioedema [147 kd] PDF